[ad_1]
However, the situation in the media market is constantly changing: if you want to support quality business journalism and want to be part of the Portfolio community, subscribe to Portfolio Signature articles. Know more
According to preliminary clinical data available in April 2020, development of the Japanese broad-spectrum antiviral drug favipiravir began in Hungary under the leadership of the Center for Research in Natural Sciences (TTK) and the University of Pécs (PTE). According to recently published data from a science-based clinical trial conducted in Japan in the past six months:
Avigan tablets containing favipiravir prevented virus multiplication in patients with moderate coronavirus treated with incipient pneumonia and relieved clinical symptoms such as fever or shortness of breath within 12 days.
– Confirmed academic Miklós György Keserű (TTK), head of the consortium developing favipiravir. He also recalled that favipiravir is an oral drug that can help reduce the burden on the health system.
“Avigan has successfully prevented patients from deteriorating and many of them have avoided intensive care,” said academician Gábor L. Kovács (PTE), director of the HECRIN Consortium, which conducts clinical trials of favipiravir in Hungary. The consortium has obtained the necessary licenses for Avigan’s clinical trial in Hungary, He added, so the use of medicine provided by the Ministry of Foreign Affairs and the Ministry of Foreign Affairs and the Japanese government can begin in the clinics of medical universities and in the National Institute of Pulmonology. In this way, Hungarian patients can now receive a proven antiviral treatment.
[ad_2]
